Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc
14 sept. 2023 17h30 HE
|
Semper Paratus Acquisition Corporation
New York, NY, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (Nasdaq: LGST) (“Semper Paratus”), a publicly traded special purpose acquisition company, today announced the...
IMUNON to Participate in the H.C. Wainwright Global Investment Conference
05 sept. 2023 08h30 HE
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces that management will participate in the H.C. Wainwright 25th...
Larkspur Biosciences Announces First-in-Class Program Targeting Novel B Cell Checkpoint
26 juin 2023 07h00 HE
|
Larkspur Biosciences, Inc.
Research foundational to Larkspur’s newly disclosed TIM-1 program published by founder Vijay K. Kuchroo in Nature WATERTOWN, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Larkspur Biosciences revealed...
Dr. Anthony E. Maida will be presenting at the Marcus Evans Evolution Summit
03 mars 2022 08h01 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), and Marcus Evans are proud to announce Dr Anthony E. Maida, Chief...
F-star Therapeutics Appoints James Sandy as Chief Development Officer
01 mars 2022 08h00 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
05 janv. 2022 08h00 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021
07 déc. 2021 09h05 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 07, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
F-star Therapeutics to Host Virtual R&D Day on December 6, 2021
29 nov. 2021 08h00 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
Celsion Corporation’s GEN-1 IL-12 Program to be Featured at Cytokine-Based Cancer Immunotherapies Summit
08 nov. 2021 08h30 HE
|
Celsion CORP
Chief Science Officer Dr. Khursheed Anwer to also Participate in Two Panel Discussions LAWRENCEVILLE, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage...
Lynx Biosciences Closes Series Seed Equity Round Led by Checkmate Capital Group
03 nov. 2021 10h00 HE
|
Lynx Biosciences, Inc.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Lynx Biosciences, Inc. ("LynxBio®"), a San Diego-based biotechnology company, today announced the successful closing of its Series Seed Preferred Stock...